Literature DB >> 6766733

Trifluorothymidine versus adenine arabinoside in the treatment of herpes simplex keratitis.

O P Van Bijsterveld, H Post.   

Abstract

Trifluorothymidine (TFT) and adenine arabinoside (ara-A) are effective antiviral drugs with a very low toxicity for the cornea. In our study no difference between these 2 drugs in antiviral activity was noted. The average healing time for TFT was 11-14 days and for ara-A 10-54 days. These data differ markedly from those of other studies. This was the result of the use of additional criteria for healing of the lesion. Not only absence of fluorescein staining of the cornea but also the absence of oedema and cystic changes in the epithelium over the previous ulcer were considered criteria for healing. In addition to clearly defined healing criteria and the healing time we found the interval between the first symptoms and the commencement of the therapy of greatest importance in the clinical evaluation of antiviral drug efficacy. An effort was made to approximate this relationship for TFT and ara-A mathematically.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766733      PMCID: PMC1039344          DOI: 10.1136/bjo.64.1.33

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers.

Authors:  P C Wellings; P N Awdry; F H Bors; B R Jones; D C Brown; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1972-06       Impact factor: 5.258

2.  A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.

Authors:  D Pavan-Langston; C H Dohlman
Journal:  Am J Ophthalmol       Date:  1972-07       Impact factor: 5.258

3.  Prospects in treating viral disease of the eye.

Authors:  B R Jones
Journal:  Trans Ophthalmol Soc U K       Date:  1967

4.  Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus.

Authors:  D J Coster; J R McKinnon; J I McGill; B R Jones; F T Fraunfelder
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

5.  Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis.

Authors:  H KAUFMAN; E L MARTOLA; C DOHLMAN
Journal:  Arch Ophthalmol       Date:  1962-08
  5 in total
  9 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine.

Authors:  E W de Koning; O P van Bijsterveld; K Cantell
Journal:  Br J Ophthalmol       Date:  1982-08       Impact factor: 4.638

3.  Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers.

Authors:  J McGill; P Tormey; C B Walker
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

4.  In vitro synergism of trifluorothymidine and ganciclovir against HSV-1.

Authors:  Jeffery A Hobden; Manish Kumar; Herbert E Kaufman; Christian Clement; Emily D Varnell; Partha S Bhattacharjee; James M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-11       Impact factor: 4.799

5.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 6.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

7.  Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.

Authors:  Joseph Colin
Journal:  Clin Ophthalmol       Date:  2007-12

Review 8.  Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

9.  Corneal epithelial dysplasia after trifluridine use.

Authors:  P C Maudgal; B Van Damme; L Missotten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.